FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Executive Summary
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
You may also be interested in...
Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy
Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share
Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy
Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share
Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa
Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)